These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM; N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693 [TBL] [Abstract][Full Text] [Related]
10. Regarding the article entitled "Effect of elexacaftor/tezacaftor/ivacaftor on annual rate of lung function decline in people with cystic fibrosis". Hoo ZH; Lai LY; Sandler RD; Daniels TE; Dawson S; Hutchings M; Wildman MJ J Cyst Fibros; 2023 May; 22(3):587. PubMed ID: 36948912 [No Abstract] [Full Text] [Related]
11. Drug-induced acne with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis. Hudson BN; Jacobs HR; Philbrick A; Zhou XA; Simonsen MM; Safirstein JA; Rotolo SM J Cyst Fibros; 2022 Nov; 21(6):1066-1069. PubMed ID: 36088208 [TBL] [Abstract][Full Text] [Related]
12. A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation. Davies JC; Sermet-Gaudelus I; Naehrlich L; Harris RS; Campbell D; Ahluwalia N; Short C; Haseltine E; Panorchan P; Saunders C; Owen CA; Wainwright CE; J Cyst Fibros; 2021 Jan; 20(1):68-77. PubMed ID: 32967799 [TBL] [Abstract][Full Text] [Related]
13. Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events. Schwarz C; Sutharsan S; Epaud R; Klingsberg RC; Fischer R; Rowe SM; Audhya PK; Ahluwalia N; You X; Ferro TJ; Duncan ME; Bruinsma BG J Cyst Fibros; 2021 Mar; 20(2):228-233. PubMed ID: 32586736 [TBL] [Abstract][Full Text] [Related]
14. Characterization of sleep in emerging adults with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor. Meltzer LJ; Gross JE J Cyst Fibros; 2024 Jan; 23(1):132-136. PubMed ID: 37210228 [No Abstract] [Full Text] [Related]
15. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA; Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085 [TBL] [Abstract][Full Text] [Related]